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Abstract
Copy number variants (CNVs) have recently been recognized as a common form of genomic variation in humans. Hundreds
of CNVs can be detected in any individual genome using genomic microarrays or whole genome sequencing technology,
but their phenotypic consequences are still poorly understood. Rare CNVs have been reported as a frequent cause of
neurological disorders such as mental retardation (MR), schizophrenia and autism, prompting widespread implementation
of CNV screening in diagnostics. In previous studies we have shown that, in contrast to benign CNVs, MR-associated CNVs
are significantly enriched in genes whose mouse orthologues, when disrupted, result in a nervous system phenotype. In this
study we developed and validated a novel computational method for differentiating between benign and MR-associated
CNVs using structural and functional genomic features to annotate each CNV. In total 13 genomic features were included in
the final version of a Naı¨ve Bayesian Tree classifier, with LINE density and mouse knock-out phenotypes contributing most
to the classifier’s accuracy. After demonstrating that our method (called GECCO) perfectly classifies CNVs causing known
MR-associated syndromes, we show that it achieves high accuracy (94%) and negative predictive value (99%) on a blinded
test set of more than 1,200 CNVs from a large cohort of individuals with MR. These results indicate that this classification
method will be of value for objectively prioritizing CNVs in clinical research and diagnostics.
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Introduction
Improvements in microarray resolution and hybridization
robustness have resulted in the widespread implementation of
genomic microarray technologies in medical research and
diagnostics. This technology is most effective in detecting genomic
deletions and duplications larger than 1kb, known as copy number
variants (CNVs). Genomic microarrays are commonly used to
identify rare, but highly penetrant, and commonly single CNVs in
patients suffering from neurological disorders such as autism [1–3],
schizophrenia [4–6] and mental retardation (MR; also known as
learning disability) [7–9]. However CNVs have also been recently
recognized as a common form of genomic structural variation:
high resolution microarrays and sequencing approaches are able
to identify 600–900 CNVs in a single individual [10–14]. Current
clinical interpretation therefore needs to contrast the frequencies
of a CNV in affected versus unaffected individuals, as well as
determining the inheritance of CNVs via parental analysis [15,16].
The identification of a CNV that is (1) relatively large, (2) overlaps
genes, (3) is rare, and (4) de novo in a patient provides a strong
indicator of clinical significance, because this combination is
extremely rare in the normal population owing to a low structural
mutation rate outside of hypervariable ‘hot spot’ regions
[10,17,18]. Increases in microarray resolution are revealing both
a much higher rate of rare CNVs than previously thought [19] and
an increasing number of genomic loci being reported that show
variable inheritance and penetrance. Such examples have been
reported for CNVs at 1q21.1 [20,21], 15q13.3 [22,23], and
16p13.11 [24,25]. These loci demonstrate that there are
limitations in considering CNVs as either benign when common
and inherited, or causal when rare and de novo.
At present up to 5% of the human genome has been shown to
vary in large scale copy number in numerous healthy controls
[13,26] and novel CNVs continue to be identified [27]. In Nguyen
et al. (2008) [28] we reported a number of genomic features whose
frequencies are significantly different in apparently benign CNV
regions compared with the genome as a whole. In particular, CNV
regions are enriched in repetitive sequences of near identical DNA
known as segmental duplications [29] and are less prone to
recombination. Furthermore, these CNV regions are character-
ized by tendencies to coincide with between-species break-points
in synteny and to be prone to elevated nucleotide substitution
rates, whilst their encoded proteins tend to exhibit elevated
evolutionary rates. In a separate study we compared a large set of
rare de novo CNVs associated with MR with CNVs identified in
healthy control individuals. This study demonstrated that MR-
associated CNVs are significantly enriched in genes whose mouse
orthologues, when disrupted, result in abnormal axon or
dopaminergic neuron morphologies, and in genes from neurode-
generative disease pathways [30]. Importantly, we showed that
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benign CNVs do not display such properties. Such observations
can thus now be used to prioritize dosage-sensitive candidate genes
for MR. Of relevance to this study is that these distinctions of MR-
associated CNVs may be exploited to aid the development of an
objective method for distinguishing disease-associated CNVs from
benign CNVs that does not rely solely on allele inheritance and
frequency in the normal population.
Although a large number of methods are available for the
computational prioritization and classification of genomic data
[31–34], none thus far has been developed specifically for CNV
data. For this study we implement a Naı¨ve-Bayesian Tree classifier
(NBTree). This hybrid approach combines a decision tree with
Naı¨ve-Bayesian classifiers, and exploits the segmentation of
decision trees and the accumulation of Naı¨ve-Bayes evidence.
There are four major advantages of decision-tree classifiers for
assigning pathogenicity to CNVs. These classifiers are (i) fast and
(ii) their results are easily comprehensible. They are (iii) very robust
to irrelevant features and (iv) classification takes into account
evidence from many attributes in arriving at a final prediction
[35]. In this study our aim was to validate the use of an NBTree,
based upon genomic features, to accurately separate disease-
associated CNVs from benign CNVs.
Results
We started by selecting genomic features (Table 1), based on
our previous observations [28,30], as the basis attribute set for
development of the classification procedure. In addition, we
collected a large cohort of CNVs identified in healthy controls
(termed ‘‘benign CNVs’’) and a large set of CNVs associated with
MR (termed ‘‘MR-associated CNVs’’) [30]. These CNVs were
used for training and testing the Naı¨ve-Bayesian Tree classifier
(NBTree). After optimization, the accuracy of the classifier was
initially assessed by applying the classifier to a small independent
set of CNVs known to be pathogenic (‘‘Decipher known
syndromes’’). We subsequently applied the classifier to a third,
much larger set of CNVs identified during routine MR microarray
diagnostics, termed ‘‘MR diagnostics CNVs’’ (see Figure S1 for
study design). Finally, we studied two further sets of CNVs whose
clinical significance is currently unknown. The first contained rare
CNVs for which inheritance could not be determined (‘‘candidate
CNVs’’). The second set contained rare, privately inherited CNVs.
Table 1. Genomic attributes investigated as potential classification features.
Genomic Feature Structural Functional Categorical Continuous
1 Type (Gain/Loss) * *
2 Length * *
3 # LINEs * *
4 LINE density * *
5 # SINEs2 * *
6 SINE density * *
7 # Segmental Duplications * *
8 Segmental Duplication Density * *
9 # Genes1 * *







14 KEGG Pathway (hsa01510) * *
15 MGI Phenotype (MP:0003631) * *
16 Gene expression * *
Each feature is either categorical or a continuous numerical feature. Furthermore, each feature relates to either a structural genomic attribute or a functional genomic
attribute.
1For these features we counted the number of genes overlapping the CNV.
2These features did not contribute to the accuracy of the classifier and were removed from the final version.
3dS = Synonymous substitution rate.
4dn =Non- synonymous substitution rate.
doi:10.1371/journal.pcbi.1000752.t001
Author Summary
Rare copy number variants (CNVs) are a frequent cause of
neurological disorders such as mental retardation (MR).
However CNVs are also commonly identified in healthy
individuals. It is therefore crucial for both diagnostic and
research applications to be able to distinguish between
disease-causing CNVs and ‘‘benign’’ CNVs occurring as
normal genomic variation. Separating these two types can
take advantage of significant differences in their genomic
contents. For example, benign CNVs are enriched in
repetitive sequences. By contrast, CNVs associated with
MR tend to have high densities of functional elements,
including genes whose mouse orthologues, when
knocked-out, lead to specific nervous system abnormali-
ties. We have developed a novel objective approach that is
effective in distinguishing MR-associated CNVs from
benign CNVs based on the presence of 13 genomic
attributes. This method is able to achieve high accuracies
in a cohort of CNVs known to cause MR and in a cohort of
individuals with unexplained MR. The development of this
technique promises to substantially improve the method-
ology for determining the pathogenicity of CNVs.
Classifying Copy Number Variation
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Development of the Classifier
We identified a total of 16 genomic features as suitable
attributes for the classifier which could be divided into either: (1)
structural features such as segmental duplication density, and (2)
functional features, such as gene density (Table 1). These
genomic attributes were also considered to be either continuous or
categorical features. To compensate for the dependencies of CNV
length on the frequencies of features (e.g. LINE, SINE, segmental
duplication and gene numbers) we also calculated the densities of
LINEs, SINEs, segmental duplications and ENSEMBL gene
models. A categorical feature was created to be set as ‘true’ when a
CNV contains at least one gene whose mouse orthologue, when
disrupted exhibits a mouse nervous system phenotype (and
otherwise ‘false’). Previously we have shown that MR CNV genes
are enriched in the KEGG neurodegenerative pathway (namely,
hsa01510). This feature was also represented in the classifier,
specifically as a categorical feature when at least one CNV gene is
a member of this KEGG pathway. Finally, we incorporated in the
classifier information regarding the gene expression variance from
microarray expression experiments performed in 176 HapMap
EBV cell lines, reasoning that dosage-sensitive genes tend to show
less variable expression levels [36,37].
Optimal balance among CNVs in the training set. The
relative frequencies of the two different classes of CNV in the
training set are very different (they are ‘imbalanced’). MR-
associated CNVs are identified in ,10% of MR patients screened
and, for these, in the large majority of cases MR is attributable to
only a single CNV (see Introduction for specific details regarding
current clinical practise for identifying clinically-relevant CNVs).
By contrast, 5 to 10 benign CNVs can be identified per non-
patient individual, depending on the microarray platform being
used [10–13]. We started by investigating the impact of this
imbalance between the two CNV classes on the accuracy of the
classifier during training. We performed 1,000 training and test
runs of the classifier each with 30 different levels of imbalance
between MR-associated and benign CNVs in the training set.
Initially, a random selection was made consisting of half of all
available benign CNVs (n = 1,413) and half of all MR-associated
CNVs (n = 82). The remaining CNVs were used subsequently as
test instances. The imbalance was then gradually decreased until
equal numbers (n = 82) of MR-associated and benign CNVs were
present in the training set (see Materials and Methods). The
most imbalanced training set, consisting of 5.5% MR-associated
and 94.5% benign CNVs (82:1,413), produced a classifier with the
lowest mean accuracy (80.4%62.9%) (Figure 1). The highest
mean accuracy (87.3%62.6%) was achieved using a balanced
training set containing 82 MR-associated and 82 benign CNVs:
this scenario takes advantage of only 5% of all available benign
CNVs for the training set.
Optimal selection of the training set. A consequence of
using a balanced training set with equal numbers of MR-
associated and benign CNVs is that not all available benign
CNVs are used during training. In order to select the optimal
training set we randomly re-sampled the training set over 10,000
iterations selecting 82 MR-associated CNVs and 82 benign CNVs,
with the remaining benign CNVs being placed in the test set. A
mean accuracy of 86% (62.8%) was obtained from these
iterations, which demonstrates that the classifier achieves a
reasonable level of accuracy irrespective of which benign CNVs
are selected for the training set. In addition, this analysis identified
an optimal subset of CNVs for training which achieved a
maximum accuracy of 95.7% and an area under the ROC
curve of 0.98 when classifying the test set of CNVs. The resulting
classifier using this optimal training set contains 5 tree nodes with
univariate splits based on the CNV length, and on the segmental
duplication, LINE, SINE and gene densities. The 6 leaves of the
tree each contain a different Bayesian classifier based on all
features used during training.
Feature Contribution to classification accuracy. The
optimal training set was obtained by training the classifier on all
16 available features. To quantify the contribution of each feature
to the accuracy of the classifier we used a leave-one-out policy for
each feature, retrained the classifier and then measured the
percentage decline in classification accuracy (Figure 2). However,
in order to exclude the effect of length on the classifier, the features
SINE, LINE, segmental duplication and gene count features were
simultaneously removed with the length feature. For example,
removing the LINE density or the length from the classifier
resulted in a 6% decrease in accuracy, whilst removing the mouse
MGI knock-out phenotypes resulted in more than a 5% decrease
in accuracy. A 4.2% decrease in accuracy was measured when any
one of the segmental duplication density, gene count, KEGG
pathway or mean ds value was removed. Removing the CNV type
(either gain or loss) resulted in a 3.7% decrease in accuracy. A
similar decrease in accuracy was observed when removing the
number of segmental duplications. Smaller effects were seen when
any one of the LINE count, SINE density, gene density and gene
expression features was removed from the classifier. By contrast,
leaving out the number of SINE elements, mean dN value, or mean
dN/dS ratio had little or no effect on the performance of the
classifier. Consequently, these three features were excluded from
the final classifier.
Validation of the Classifier
Application to MR Syndromes. The Decipher database of
known syndromes associated with genomic structural variants
(https://decipher.sanger.ac.uk) provides a large set of pathogenic
CNVs that is suitable for the independent validation of the
classifier. In this database the genomic locations (based on
microarray studies) of 58 syndromes are reported, 32 of which
are associated with MR. We applied the classifier to these 32
Figure 1. Effect of the imbalance between MR-associated and
benign CNVs in the training set on the accuracy of the
classifier. This figure shows the relationship between the fraction of
available benign CNVs used in the training set and the accuracy of the
classifier (calculated over 1,000 independent test and training runs).
Maximum accuracy is achieved with a similar number of MR-associated
and benign CNVs in the training set (,5% of the benign CNV instances
available).
doi:10.1371/journal.pcbi.1000752.g001
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genomic regions and found that 31 regions were classified as
pathogenic. The 80kb critical region of Rubinstein-Taybi
Syndrome was not correctly classified (Table S1). This region is
a composite of overlapping microdeletions, ranging in size from
1.5–3.5Mb, identified in 3 individuals with this syndrome. When
we tested these three regions individually each was classified as
pathogenic. From this we concluded that the classifier was able to
correctly identify known pathogenic CNVs.
Application to MR diagnostics. We performed a second
more extensive study to validate the accuracy of the classifier using
an independent set of 584 MR patients in which 1,203 CNVs (the
set ‘‘MR diagnostics’’) had been identified during routine
diagnostics using Affymetrix 250k SNP microarrays. These CNVs
were identified as being associated with MR (n = 49) based on de novo
occurrence and the absence of similar CNVs in the normal
population, or as being benign CNVs (n = 1,154) known to be
present in the normal population. Of the 1,203 CNVs in the
validation set, 94% of the CNVs were classified correctly, with a
sensitivity of 88% and a specificity of 94% (Figure 3a). More
specifically, 43 of 49 MR-associated CNVs were correctly classified,
37 of which had a distance of less than 0.1 from the MR class,
showing that these classifications have a high confidence. Each node
of the NBTree contains a Bayesian classifier resulting in the most
likely class (benign or MR-associated) for each CNV being
predicted. In addition, the probability (a distance function) is
calculated that a CNV belongs to the MR-associated CNV class or
to the benign CNV class. The overall false positive rate was 0.05 and
the false negative rate 0.12. The positive predictive value was 0.38
(indicating the number of CNVs correctly classified as MR, divided
by the total number of CNVs classified as being MR). The negative
predictive value was 0.99 (indicating the number of CNVs correctly
classified as benign, divided by the total number of CNVs classified
as benign) (Table 2). 1,085 of 1,154 benign CNVs (94%) were
correctly classified whilst 69 (6%) were incorrectly classified as an
MR-associated CNV (Table 2). To exclude the possibility that the
initial training set did not contain sufficient biological coverage to
represent the variance of each classification feature, and to train the
optimal classifier, we combined the test and training sets and
retrained the classifier. The accuracy of the resulting classifier was
then tested on the validation set. The training set was jack-knifed to
contain equal numbers of MR-associated and benign CNVs
(n = 164) and 10,000 iterations were performed. The mean
accuracy across all iterations was 76% and the maximum
achieved accuracy was 94%, equal to that gained with the smaller
training set. Thus we conclude that the training set with 82 MR-
associated and 82 benign CNVs contained sufficient biological
coverage to model the data accurately.
To further investigate the contribution of particular features to
misclassification rates we calculated the mean values for each
feature in the correctly and incorrectly classified CNV groups
(Table S2). This highlighted some general differences between
correctly and incorrectly classified CNVs. For example, 78% of
the incorrectly classified benign CNVs were copy number gains
and contained, on average, fewer segmental duplications than
correctly classified benign CNVs. In addition, 86% of the correctly
classified MR-associated CNVs contain at least one gene whose
mouse orthologue knockout results in a nervous system phenotype,
whereas only 33% of the incorrectly classified MR-associated
CNVs contain such genes. We also noted that correctly classified
MR-associated CNVs have an average genomic size of 7.7Mb,
whereas CNVs incorrectly classified as benign have, on average, a
much smaller size of 1.1Mb. Likewise, incorrectly classified benign
CNVs also had a smaller average size (319kb) than benign CNVs
correctly classified (492kb). We therefore investigated the accuracy
of the classifier on 971 CNVs smaller than 1.1Mb in more detail.
For these smaller CNVs, 9 of the 13 MR-associated CNVs as well
as 890 of the 958 benign CNVs were classified correctly. The
performance of the classifier on these small CNVs was comparable
to the overall performance on the complete validation set with an
accuracy of 93% and specificity of 93%, with the exception of
sensitivity which dropped by 18% to 70%. Analysis of the genomic
features in smaller CNVs showed that despite differences in CNV
lengths, small MR-associated CNVs show many similarities to
larger MR-associated CNVs such as similar SINE and gene
densities (Table S2).
Application of the Classifier to CNVs of unknown clinical
significance. Finally we sought to use our classifier on two
further CNV datasets with unknown clinical significance, termed
candidate CNVs and rare inherited CNVs. We first selected a set
of 53 rare CNVs identified in the clinic, not known to vary in copy
number among the general population, for which inheritance
could not be established due to the unavailability of one or both
parents. Due to their unknown inheritance and rare status, we are
unable to determine using current diagnostic procedures whether
these CNVs are indeed causal. In total, 46 of these 53 CNVs were
classified as MR-associated CNVs (Table 2). We also applied the
classifier to a set of rare, privately inherited CNVs that are not
known to vary in the general population (Figure 3b). Twenty-
seven of the 41 rare inherited CNVs were classified as an MR-
associated CNV, and 14 were classified as a benign CNV
(Table 2) displaying a significant enrichment in the number of
CNVs classified as MR-associated when compared to size matched
CNVs selected randomly from the genome (p = 7.061023).
Figure 2. Analysis of the relative contribution of each genomic
feature to the CNV classifier. Both structural and functional
genomic features are evaluated for their impact on classification
accuracy. This analysis is performed by measuring the decrease in
accuracy of the classifier as each classification feature is removed
individually. KEGG Pathway refers to the CNV region containing at least
one gene implicated in a KEGG neurodegenerative pathway, and MGI
Pheno refers to the CNV region containing at least one gene displaying
a nervous system phenotype in a knockout mouse. Gene Expression
refers to the stability of gene expression of genes present in the CNV.
Removal of the LINE density from the classifier results in the largest
decrease in accuracy (6%) whilst removing MGI knockout phenotypes
results in a drop of 5% in accuracy. The number of SINE elements, the
non-synonymous substitution rate (dN), and the ratio of the synony-
mous versus non-synonymous substitution rate (dN/dS) individually
have no effect on the accuracy of the classifier.
doi:10.1371/journal.pcbi.1000752.g002
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Discussion
In this study we present a novel computational method to
objectively identify clinically relevant CNVs using an NBTree
classifier and 13 diverse genomic features. This is the first
description of such a method applied to CNVs that can
significantly improve interpretation of this important class of
genomic variation. Our classification method has been validated
on a set of 1,203 CNVs detected in 584 patients with MR,
achieving a high accuracy (94%), with a sensitivity of 88% and a
specificity of 94% (Figure 3a).
Several other computational methods have been developed
previously to predict if disruption or disturbance of genomic
elements have pathogenic consequences. Often these methods are
focused on identifying disease genes or on predicting if mutation or
splicing events are pathogenic [31–34]. Such methods make use of
protein structure and stability measures, and phylogenetic or
sequence conservation data [38,39], and often cross-validate their
predictions using OMIM (Online Mendelian Inheritance in Man)
data [40]. These approaches may be less applicable for larger
structural variants such as CNVs because they predict the effect of
a single change on a single disease gene, rather than a large change
involving many genes. Our approach differs in that we directly
predict the causal CNV from genome-wide copy number scans on
the basis of the distinguishing features of benign and disease-
causing CNVs. In addition, OMIM does not provide a suitable
source for validating the performance of a classification method for
CNVs as dosage-sensitive genes are largely underrepresented in
this database (,5% of the entries describe haploinsufficient genes
[41]), and because a precise mapping of CNVs in OMIM is
lacking. In contrast to OMIM, the Decipher database list of
known syndromes (https://decipher.sanger.ac.uk) provides a
suitable list of CNVs for external validation of the classifier with
high-resolution mapping of their genomic locations. Our classifi-
cation method correctly identified all the CNVs listed in this
database as causing MR-associated syndromes.
The classifier incorporated specific knowledge about CNVs via
13 diverse structural and functional genomic features (including a
number of different transposable element types). The proximity of
these elements to CNVs has been reported previously and it has
Figure 3. Benign CNVs are separable from MR-associated CNVs using a distance function that reflects the probability that a CNV
belongs to the MR-associated CNV class. The CNVs are ranked and their probability of belonging to the MR-associated CNV class is plotted, A)
1,203 CNVs with known inheritance collected from routine diagnostics are classified with a sensitivity of 88% and a specificity of 94%. 1,085 of the
1,154 of the common inherited CNVs were correctly classified (blue), and 43 of 49 CNVs previously associated with MR were correctly classified as MR-
associated (green). 6 CNVs which had been interpreted as not being associated with MR, were classified as MR-associated (red), as well as 69 CNVs
classified as MR-associated which had previously been interpreted as benign (purple). B) Similarly, 41 rare inherited CNVs with unknown clinical
significance are classified, 27 of which were classified as MR-associated with a MR distance .0.5 (green), and 14 were classified as benign (MR
distance ,0.5, blue).
doi:10.1371/journal.pcbi.1000752.g003
Table 2. Application of the classifier to CNVs obtained in routine diagnostics of patients with mental retardation.
Classifier Output Validation Set (Rare de novo vs. commonly inherited CNVs) Application Set (CNVs of unknown clinical significance)
MR CNVs (rare de novo)
Benign CNVs (commonly
inherited) Sub Total Rare Inherited
Rare CNVs of unknown
inheritance
MR 43 69 112 27 46
Benign 6 1,085 1,091 14 7
Total 49 1,154 1,203 41 53
The accuracy of the classifier developed was tested on an independent cohort of CNVs. Phase 1 contained the validation set of 1,203 CNVs known to be either rare de
novo or commonly inherited. 43 of the 49 rare de novo CNVs known to be associated with MR were correctly classified, and 1,085 of the 1,154 common inherited CNVs
known to be benign were correctly classified, thus giving an overall classification accuracy of 94%. The false positive rate was 0.05 and the false negative rate was 0.12.
The positive predictive value was 0.38 and the negative predictive value was 0.99. Phase 2 consisted of the application set containing 94 CNVs of unknown clinical
significance. Of the 41 rare inherited CNVs the classifier identified 27 CNVs as MR-associated and 14 as being benign. 53 candidate CNVs for which the inheritance could
not be determined were also classified, from which 46 were classified as being MR and 7 CNVs were classified as being benign.
doi:10.1371/journal.pcbi.1000752.t002
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been hypothesized that they mediate the formation of recurrent
CNVs [18,26,42]. We confirm previous results that benign CNVs
are enriched in both LINE and segmental duplication elements
[13,28] and show that both the LINE density and the segmental
duplication density substantially contribute to the classifier’s
accuracy (Table S2). Previous studies have also reported that
CNV gains are enriched in many of the same features as CNV
losses [30]. Our feature contribution results support this finding:
when the CNV type was removed from the classifier only a 3.7%
decrease in accuracy was observed, and 7 additional features had a
greater contribution to the classifier’s accuracy. In addition to
these transposable elements, we included functional genomic
elements which have recently been shown to assist in distinguish-
ing benign from MR-associated CNVs [30,43]. The significant
enrichment of MGI mouse nervous system phenotypes in MR loss
CNVs has previously been reported [30]. We show that the MGI
mouse knock-out phenotype feature is effective in distinguishing
benign from MR-associated CNVs: 80% of all MR-associated
CNVs contain one or more genes whose unique orthologue’s
disruption in mouse reveals a nervous system phenotype, whereas
benign CNVs only rarely contain such genes (Table S2).
Despite the MGI mouse phenotype dataset being incomplete,
this feature contributes greatly to the classifier’s accuracy (5%). To
date, gene knockout experiments with recorded ontology based
phenotype information have been performed for approximately
5,000 of the possible 15,287 genes with mouse 1:1 orthologues
[44,45]. Furthermore the MGI phenotype data are included in the
classifier as a binary feature (which is labelled as ‘true’; when a
CNV contains 1 or more genes exhibiting a nervous system
phenotype; MP:0003631). However, as the MGI phenotype
dataset is incomplete, our approach is conservative with respect
to missing values. This is because CNVs overlapping genes whose
disruption does not result in a nervous system phenotype are
weighted equally to those CNVs overlapping genes whose
disruption phenotypes are currently unknown. Thus, we expect
that increased coverage by the MGI mouse knock-out dataset will
significantly improve the accuracy of the classifier. In addition,
further genomic features such as CpG islands or conserved non-
coding regions [46] can now be tested for their potential to
improve the accuracy of this approach. Nevertheless, as the
densities of many genomic features are strongly correlated [28], it
is likely that the addition of further features to the classifier will not
result in a substantial improvement in predictive power.
Most of the CNVs we used to train the classifier were identified
on low-resolution (BAC–based) microarray platforms. In contrast,
the replication set contained CNVs collected solely from
Affymetrix 250k SNP microarrays. Despite the different micro-
array technologies used, only a negligible decrease in classification
accuracy (21.7%) was observed between the training and the
replication set. This indicates that the classifier is platform-
independent and will not require retraining when used on data
generated from comparable microarray platforms.
MR-associated CNVs discovered thus far are, in general, larger
than benign CNVs [30]. Previously developed CNV risk
assessments for identifying disease-associated CNVs use a length
greater than 3Mb as a distinguishing criterion [16]. Closer
inspection of the MR-associated CNVs from our validation study
indeed revealed a larger mean length (6.8Mb) compared to the
benign CNVs (474kb). Despite this large size, 25% of the MR-
associated CNVs in the validation set were smaller than 1.1Mb.
We separately tested the accuracy of the classifier on CNVs
smaller than 1.1Mb which revealed it to exhibit a decrease in
sensitivity (218%) but still a high accuracy (93%). As might be
expected, small MR-associated CNVs showed a decrease in the
number of MGI knock-out genes displaying a nervous system
phenotype, but their SINE and gene densities are comparable to
those of larger MR-associated CNVs (Table S2). Importantly,
the classifier was still able to correctly classify 9 of the 13 small
MR-associated CNVs, demonstrating the advantage of the
classifier in comparison to conventional interpretation methods
which often are unable to clearly identify clinically relevant CNVs
unless specific information about their genomic content is known
[47].
Although current clinical interpretation of CNVs focuses on
large, rare and de novo CNVs, an increasing number of genomic
loci being reported show variable inheritance and penetrance [20–
24]. Our replication study contained a number of such CNVs,
including CNVs at 1q21.1 and 15q13.3 which, in addition, show
variation in genomic size and content [20–23]. Three rare
inherited CNVs encompassing the 1q21.1 critical region were all
classified as associated with MR, even though their genomic
breakpoints differed. Two rare de novo CNVs in the 15q13.3 region
were classified differently, one as benign and one as pathogenic. In
addition, three inherited CNVs at this locus were all classified as
benign. Interestingly, the distal breakpoint for all five CNVs was
identical whereas the proximal breakpoint of the four CNVs
classified as benign was extended by an additional 150kb. This
difference in classification is explained by the fact that the 150kb
region showed a higher repeat element count and density due to
repetitive elements surrounding the 15q13.3 critical region (Table
S2) [23]. This particular example highlights the current challenge
in clinical interpretation of CNVs which relies on the availability
of large control datasets. We do not claim that our classification
method replaces the need for such datasets. Our method does
show that 27 out of 41 (66%) rare inherited CNVs identified in
patients contain genomic features similar to previously recognized
MR-associated CNVs, a significant proportion when compared to
the remainder of the genome (Figure 3b). This provides
independent support for the clinical relevance of this group of
CNVs and shows that the interpretation of CNVs should not be
limited to rare de novo CNVs with a fully penetrant dominant effect
[48]. Furthermore, in the set of 53 rare CNVs with unknown
inheritance, 46 CNVs were classified as being MR-associated, the
vast majority with high confidence. These rare CNVs with
unknown inheritance demonstrate strong similarities to rare de novo
CNVs in that they have a low segmental duplication density, a
high SINE density, often contain genes whose mouse knockouts
result in nervous system phenotypes, have similar gene expression
values and similar synonymous substitution rates. This suggests
that these rare CNVs with unknown inheritance are indeed similar
in pathoetiology to rare de novo CNVs and thus can be considered
strong candidates for being causal CNVs. The ability of the
classifier to identify such CNVs of unknown inheritance should be
of great benefit to the diagnostic communities.
This CNV classifier may also be informative of disorders other
than mental retardation. This is of particular relevance because
CNVs have recently been associated with other neurodevelop-
mental disorders such as autism and schizophrenia [1,4,5] but
screening for causal CNVs in these diseases has yet to be
implemented in most clinics. Interestingly, many of the CNVs
associated with autism and schizophrenia, as well as mental
retardation, contain genes whose proteins are involved in
neurotransmission or in synapse formation and maintenance.
This supports the existence of shared biological pathways that are
disrupted in each of these neurodevelopmental disorders [49]. Our
CNV classifier trained on MR CNVs may therefore already have
predictive power for CNVs in other neurological disorders. It is
likely, however, that this predictive power can be further
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optimized by retraining the classifier using disease-specific CNVs.
In addition, the KEGG and MGI features selected for the MR
patient cohort are also easily configurable for pathways and
phenotypes which are more relevant to these other disease cohorts.
For this reason we have made the Java source code of the CNV
classifier, called GECCO, freely available (see Materials and
Methods).
In conclusion, we have developed a novel objective method to
identify disease-associated CNVs which has overcome several
limitations with current CNV interpretation methodology. Our
NBTree classifier is able to distinguish between MR-associated
CNVs and benign CNVs with high accuracy without the use of
data from large control cohorts or parental samples. Results
indicate that computational classification methods can be used for
objectively prioritizing CNVs in clinical research and diagnostics.
The tool for classifying CNVs, called GECCO (Genomic
Classification of CNVs Objectively), as well as the Java source
code, are readily available online. The benefits of such methods
will increase with advancements in microarray technology, which
already identifies many thousands of such structural variants per
individual [50–53], and in whole genome resequencing technol-
ogy,. Establishing objective criteria and methods for interpretation
of these genomic variants will be crucial for implementation of
these technologies in a clinical setting.
Materials and Methods
Classifier Development
In this study we investigate if rare de novo CNVs and commonly
inherited CNVs could be successfully classified without the use of
inheritance information. In order to achieve this we collected from
the literature a large number of rare CNVs known to be de novo
(n = 164) and a number of common CNVs known to be benign
(n = 1,413). These CNVs were used for training and testing the
classifier. A total of 20 genomic features were initially investigated.
Initially 16 features were selected as attributes during the
development of the classifier, which was then further optimized
to a set of 13 features (Table 1). To test the accuracy of the
classifier we first tested the classifier on a set of CNVs previously
identified as being associated with MR (Decipher known
syndromes), and then created an independent validation set
containing rare de novo and common inherited CNVs, collected
from routine diagnostics, to be used in a validation study (MR
diagnostic CNVs). Finally two application sets were created
containing CNVs without a clinical interpretation that were either
a) candidate CNVs, due to unavailability of parental samples, or b)
rare privately inherited CNVs.
Data Sets
The CNVs used during the training and test phase (164 rare de
novo CNVs termed ‘‘MR-associated CNVs’’ and 1,413 common
inherited CNVs termed ‘‘benign CNVs’’) were identified on a
number of different microarray platforms in previously published
studies [15,19,28,30]. All aberrations were mapped using HG17
coordinates and converted when necessary using UCSC liftOver
[54]. The Decipher known syndromes’ (https://decipher.sanger.
ac.uk/) dataset contained 32 pathogenic CNVs based on
microarray studies and associated with MR. The remaining 26
syndromes were excluded as they do not have either mental
retardation as a prominent phenotype or a fully penetrant
phenotype.
MR Diagnostics and application datasets were collected
through in-house routine diagnostics using Affymetrix 250k SNP
microarrays (Affymetrix, Santa Clara, USA), and consisted of 584
samples containing 1,297 CNVs. Regions were excluded that
contained fewer than 5 microarray targets, that were smaller than
10kb in size or that were the result of a mosaic or complex
chromosomal aberration. In total, the validation/application set
contained 49 rare de novo CNVs, 41 rare inherited CNVs, 53
candidate CNVs and 1,154 common inherited CNVs.
Classifier Training
Initially a training set was created by randomly selecting 82 of
the 164 rare de novo CNVs with an equal number of commonly
inherited CNVs. The remaining CNVs were placed in the test set.
The NBTree classification algorithm as implemented in Weka
3.6.0 [55] was selected and incorporated into our Java based tool
called GECCO (Genomic Classification of CNVs Objectively). An
executable version and all source code for GECCO are readily
available via http://genomegecco.sourceforge.net. NBTree is a
hybrid method combining a decision tree with Naı¨ve-Bayesian
classifiers. The Naı¨ve-Bayesian classifiers calculate the posterior
probability (a distance function) that the CNV belongs to either
class (MR-associated CNV or benign CNV).The definition of the
training set was then investigated. Given the imbalance that exists
in the data (see Results) we sought to incorporate this prior into the
training set. We tested increasingly imbalanced versions of the
training set, starting with the most unbalanced training set, by
placing half of all available CNVs in the training set (164 de novo
and 2826 common inherited), and gradually decreasing the
imbalance until the training set contained only 5% (n = 143) of
all available common inherited CNVs. The training set imbalance
was then further tested in 1% decrements until the minimum was
reached of 82 rare de novo CNVs and 28 common inherited CNVs.
Once an optimal balance of CNV classes in the training set was
identified the optimal subset of the CNVs in the training set was
determined. This was achieved by randomly selecting CNVs as
training and test instances over 10,000 iterations and then
identifying the set that produced the maximum accuracy. In
addition, enrichment analysis of the rare inherited CNVs was
performed by generating 1,000 sets of random genomic regions
matched for size against the rare inherited CNVs and the
proportion of sets with greater than or equal to 27 CNVs classified
as being MR was calculated.
Genomic Features used for Classification
In total 20 different genomic features were investigated as
potential classifier attributes. The variance inflation factor (VIF)
was used to measure the co-linearity within the model across the
repeat, gene and evolution measures (simple repeats, repeat
masker, LINE, SINE, long terminal repeats, RNA gene elements,
segmental duplications, ENSEMBL genes, mean non-synonymous
substitution rate (dN), synonymous substitution rate (dS) and the dN/
dS ratio of genes). Based on the VIF, features were removed until
the model contained only independent features resulting in 16
different structural and functional genomic features that were used
subsequently for training the classifier (Table 1). The included
structural features were CNV type (loss:gain), CNV length, the
numbers of LINE, SINE and segmental duplication elements lying
within the CNV, as well as the densities of the LINE, SINE and
segmental duplication elements. The density values were deter-
mined as the number of elements per base pair. Segmental
duplications were downloaded from the UCSC table genomic-
SuperDups. The numbers of LINE and SINE elements were
extracted from the UCSC table from rmsk and the RNA gene
elements from sno/miRNA.
The functional genomic features consisted of the gene count,
gene density and the variance in gene expression levels, the mean
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non-synonymous substitution rate (dN), synonymous substitution
rate (dS) and the dN/dS ratio. In addition KEGG pathway and MGI
knockout phenotypes were added as features. Genes involved in
the KEGG (Kyoto Encyclopedia of Genes and Genomes)
neurodegenerative pathway (hsa01510) [56] were added as a
categorical feature. This pathway includes KEGG genes belonging
to KEGG Pathways section 5.2, namely Alzheimer’s disease
(KEGG pathway 05010), Parkinson’s disease (KEGG pathway
05020), Amyotrophic Lateral Sclerosis (KEGG pathway 05030),
Huntington’s disease (KEGG pathway 05040), Dentatorubropal-
lidoluysian atrophy (KEGG pathway 05050) and Prion Diseases
(KEGG pathway 05060). KEGG genes were mapped to NCBI
Entrez genes using associations provided by KEGG. Genes which
were annotated as having the MGI mouse knockout phenotype,
MP:0003631: nervous system phenotype were also added as a
categorical feature. These genes were identified via human NCBI
genes whose mouse orthologue’s disruption had been assayed and
were obtained from the Mouse Genome Informatics (MGI)
resource (http://www.informatics.jax.org, version 3.54) [45].
Substitution rates were obtained from EPGD [57]. The stable
expression was calculated via the standard deviation of log2
intensities across 176 Hapmap cell lines (CEU and YRI)
hybridized onto an Affymetrix GeneChip Human Exon 1.0 ST
array (GSE7761).
Supporting Information
Figure S1 Workflow used to develop the classifier. The classifier
is able to distinguish between MR CNVs and benign CNVs based
upon solely genomic features without the use of inheritance
information. Several classification methods are tested. A training
set consisting of both MR and benign CNVs is selected and the
genomic features extracted. These data are used to train the
classifier which is then evaluated with a separate test set of CNVs.
The process of training set selection is repeated until an optimal
performance is obtained. Subsequently, the classifier is validated
on an independent set of MR and benign CNVs.
Found at: doi:10.1371/journal.pcbi.1000752.s001 (0.05 MB
DOC)
Table S1 Classification Results of 32 MR syndromes from the
DECIPHER database. The chromosome location, syndrome
name, as well as the CNV length and type are given. The
classification results are shown with the MR distance measure,
showing the confidence of each classification decision.
Found at: doi:10.1371/journal.pcbi.1000752.s002 (0.06 MB
DOC)
Table S2 Mean (and standard deviation) of each genomic
feature used by the classifier during the validation and application
studies. For each class of CNV the feature mean and (standard
deviation) for the correctly and incorrectly classified CNVs are
indicated.
Found at: doi:10.1371/journal.pcbi.1000752.s003 (0.06 MB
DOC)
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